Close Menu

NEW YORK (GenomeWeb) – Guardant Health said after the close of the market Monday that it has commenced a public offering of up to 4.5 million shares of its common stock. In addition, the company expects to grant underwriters a 30-day option to purchase an additional 675,000 shares.

JP Morgan Securities and BofA Merrill Lynch are serving as joint lead book-running managers. A registration statement related to the securities has been filed with the SEC but is not yet effective.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.